Medline (NASDAQ:MDLN) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft began coverage on shares of Medline (NASDAQ:MDLN) in a report issued on Monday morning, MarketBeat.com reports. The firm issued a hold rating and a $40.00 price objective on the stock.

A number of other brokerages have also commented on MDLN. Evercore ISI initiated coverage on Medline in a report on Monday. They set an “outperform” rating and a $50.00 price target on the stock. Cowen started coverage on shares of Medline in a research report on Monday. They set a “buy” rating on the stock. The Goldman Sachs Group started coverage on shares of Medline in a research note on Monday. They issued a “buy” rating and a $49.00 price target for the company. Wall Street Zen upgraded shares of Medline to a “hold” rating in a research note on Saturday. Finally, Morgan Stanley began coverage on Medline in a research report on Sunday. They issued an “overweight” rating and a $48.00 target price for the company. Twenty-three analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $46.70.

Medline Stock Performance

Shares of MDLN opened at $42.72 on Monday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Activity at Medline

In other news, Director Andrew J. Mills acquired 2,586,206 shares of Medline stock in a transaction on Thursday, December 18th. The stock was bought at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the purchase, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares of the company’s stock, valued at approximately $136,350,759.20. This trade represents a 55.88% decrease in their position. The SEC filing for this sale provides additional information.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Numerous analysts initiated buy/overweight ratings (Barclays, Jefferies, Bank of America, JPMorgan, Wolfe, Mizuho, TD Cowen, Stifel, Piper Sandler, Bernstein, J.P. Morgan, William Blair, Robert W. Baird, Truist). Several targets sit in the $46–$52 range, implying notable upside and helping fuel buying interest. Medline Stock Surges on Post‑IPO Buy Notes
• Positive Sentiment: Jefferies highlighted Medline’s $25 billion supply‑chain scale and gave a “buy” in its coverage debut — a validation of the company’s scale and margin expansion thesis that investors favor. Jefferies Coverage
• Positive Sentiment: Benzinga and other outlets note Medline raised ~$7 billion in its IPO and is being praised for a “prime vendor” model, branded mix shift and margin expansion potential — fundamental reasons analysts cite for buy ratings. Analysts Say Medline Has The Secret Sauce
• Neutral Sentiment: Valuation checks and commentary: several writeups assess MDLN near discounted cash‑flow estimates or “fairly priced” after the recent stability — these limit runaway upside and suggest gains are tied to multiple expansion as much as earnings. Valuation Check
• Neutral Sentiment: Short interest report in the period shows effectively zero/ambiguous data (odd reporting numbers). No clear short‑squeeze signal — treat short‑interest data as non‑contributory for now.
• Negative Sentiment: Some shops initiated neutral/hold ratings with lower targets (BNP Paribas $38 target, Deutsche Bank $40, Wells Fargo $42, Rothschild $42). Those lower targets cap consensus upside and could pressure the stock if follow‑through selling emerges.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.